Teva Pharmaceutical Industries Limited (TEVA) Shares Sold by Palisade Capital Management LLC NJ

Palisade Capital Management LLC NJ lessened its stake in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 99.7% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 18,100 shares of the company’s stock after selling 6,064,422 shares during the quarter. Palisade Capital Management LLC NJ’s holdings in Teva Pharmaceutical Industries Limited were worth $319,000 as of its most recent SEC filing.

Other hedge funds also recently made changes to their positions in the company. Capital Research Global Investors raised its holdings in Teva Pharmaceutical Industries Limited by 13.8% in the second quarter. Capital Research Global Investors now owns 76,325,059 shares of the company’s stock valued at $2,535,518,000 after acquiring an additional 9,260,426 shares in the last quarter. Franklin Resources Inc. raised its holdings in Teva Pharmaceutical Industries Limited by 11.1% in the second quarter. Franklin Resources Inc. now owns 66,796,897 shares of the company’s stock valued at $2,218,958,000 after acquiring an additional 6,685,844 shares in the last quarter. FMR LLC raised its holdings in Teva Pharmaceutical Industries Limited by 16.7% in the second quarter. FMR LLC now owns 42,844,979 shares of the company’s stock valued at $1,423,310,000 after acquiring an additional 6,115,853 shares in the last quarter. Northern Cross LLC raised its holdings in Teva Pharmaceutical Industries Limited by 14.0% in the second quarter. Northern Cross LLC now owns 17,795,579 shares of the company’s stock valued at $591,169,000 after acquiring an additional 2,184,172 shares in the last quarter. Finally, Nordea Investment Management AB raised its holdings in Teva Pharmaceutical Industries Limited by 2.5% in the second quarter. Nordea Investment Management AB now owns 12,884,810 shares of the company’s stock valued at $428,033,000 after acquiring an additional 311,894 shares in the last quarter. 56.45% of the stock is owned by institutional investors.

Several brokerages recently weighed in on TEVA. Royal Bank Of Canada reduced their target price on shares of Teva Pharmaceutical Industries Limited from $21.00 to $15.00 and set an “underperform” rating on the stock in a report on Monday, September 18th. Wells Fargo & Company reissued a “market perform” rating on shares of Teva Pharmaceutical Industries Limited in a report on Thursday, October 5th. Credit Suisse Group set a $39.00 price objective on shares of Teva Pharmaceutical Industries Limited and gave the stock a “buy” rating in a report on Thursday, August 3rd. Maxim Group reissued a “hold” rating and set a $15.50 price objective on shares of Teva Pharmaceutical Industries Limited in a report on Thursday, September 14th. Finally, Morgan Stanley cut their price objective on shares of Teva Pharmaceutical Industries Limited from $14.00 to $7.00 and set an “underweight” rating on the stock in a report on Friday. Five analysts have rated the stock with a sell rating, eighteen have given a hold rating, six have given a buy rating and one has given a strong buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus target price of $24.76.

Shares of Teva Pharmaceutical Industries Limited (TEVA) opened at $11.40 on Monday. The company has a debt-to-equity ratio of 1.20, a quick ratio of 0.66 and a current ratio of 0.96. The stock has a market capitalization of $11,582.40, a P/E ratio of 2.63 and a beta of 0.52. Teva Pharmaceutical Industries Limited has a 52-week low of $10.85 and a 52-week high of $42.90.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last posted its quarterly earnings results on Thursday, August 3rd. The company reported $0.99 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $1.06 by ($0.07). The firm had revenue of $5.69 billion for the quarter, compared to analyst estimates of $5.72 billion. Teva Pharmaceutical Industries Limited had a negative net margin of 24.35% and a positive return on equity of 15.70%. The business’s revenue was up 12.9% on a year-over-year basis. During the same period in the prior year, the company posted $1.25 earnings per share. research analysts predict that Teva Pharmaceutical Industries Limited will post 4.06 earnings per share for the current year.

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 12th. Investors of record on Tuesday, November 28th will be given a dividend of $0.085 per share. This represents a $0.34 annualized dividend and a dividend yield of 2.98%. Teva Pharmaceutical Industries Limited’s dividend payout ratio is currently -15.80%.

ILLEGAL ACTIVITY NOTICE: “Teva Pharmaceutical Industries Limited (TEVA) Shares Sold by Palisade Capital Management LLC NJ” was published by Community Financial News and is the property of of Community Financial News. If you are accessing this story on another site, it was copied illegally and reposted in violation of U.S. & international trademark & copyright law. The correct version of this story can be read at https://www.com-unik.info/2017/11/06/teva-pharmaceutical-industries-limited-teva-shares-sold-by-palisade-capital-management-llc-nj.html.

Teva Pharmaceutical Industries Limited Profile

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Institutional Ownership by Quarter for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

What are top analysts saying about Teva Pharmaceutical Industries Limited? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Teva Pharmaceutical Industries Limited and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit